← Eichor
Condition: Chromosomal Rearrangement Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Chromosomal Rearrangement

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Phase 3 · 1 location(s) · Tata Memorial Hospital · NCT05236946Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B C
Phase 1/Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT06249191A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07101497A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Ac
Phase 1/Phase 2 · 74 location(s) · Nuvalent Inc. · NCT05384626Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Pres
Phase 2 · 27 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT06620835A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (A
Phase 1/Phase 2 · 63 location(s) · Nuvalent Inc. · NCT05118789A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT
Phase N/A · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07559695SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Mutational Oncology in Clinical Practice
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06020625SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurren
Phase 1 · 4 location(s) · Uma Borate · NCT06222580ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05014464Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Phase 1 · 4 location(s) · Tyra Biosciences, Inc · NCT06160752Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07537738Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT04432714Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Phase 2 · 65 location(s) · Taiho Oncology, Inc. · NCT05727176Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373Ziftomenib Maintenance Post Allo-HCT
Phase 1 · 2 location(s) · Massachusetts General Hospital · NCT06440135Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05681780HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Phase 2/Phase 3 · 1 location(s) · Hutchmed · NCT04353375The Contribution of Optical Mapping to the Characterization of Chromosomal Rearrangements in Patients With Neurodevelopm
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07133789A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patien
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT05886049A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT06073938Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NA · 46 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT05122806A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Phase 2 · 19 location(s) · Elevar Therapeutics · NCT07359820Microfluidic Chip vs Density Gradient Centrifugation on the Euploidy Rate of Pre-implantation Genetic Testing
NA · 1 location(s) · Professor Ernest Hung-Yu Ng · NCT06023472Olverembatinib for FGFR1-rearranged Neoplasms
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05521204A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1/Phase 2 · 57 location(s) · Syndax Pharmaceuticals · NCT04065399A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients
Phase 2 · 2 location(s) · Mehmet Akce · NCT06728410
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.